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Abstract
Background: Epithelial-mesenchymal interactions are critical in regulating many aspects of vertebrate embryo
development, and for the maintenance of homeostatic equilibrium in adult tissues. The interactions between epithelium
and mesenchyme are believed to be mediated by paracrine signals such as cytokines and extracellular matrix components
secreted from fibroblasts that affect adjacent epithelia. In this study, we sought to identify the repertoire of microRNAs
(miRNAs) in normal lung human fibroblasts and their potential regulation by the cytokines TNF-a, IL-1b and TGF-b.
Methodology/Principal Findings: MiR-155 was significantly induced by inflammatory cytokines TNF-a and IL-1b while it
was down-regulated by TGF-b. Ectopic expression of miR-155 in human fibroblasts induced modulation of a large set of
genes related to ‘‘cell to cell signalling’’, ‘‘cell morphology’’ and ‘‘cellular movement’’. This was consistent with an induction
of caspase-3 activity and with an increase in cell migration in fibroblasts tranfected with miR-155. Using different miRNA
bioinformatic target prediction tools, we found a specific enrichment for miR-155 predicted targets among the population
of down-regulated transcripts. Among fibroblast-selective targets, one interesting hit was keratinocyte growth factor (KGF,
FGF-7), a member of the fibroblast growth factor (FGF) family, which owns two potential binding sites for miR-155 in its 39-
UTR. Luciferase assays experimentally validated that miR-155 can efficiently target KGF 39-UTR. Site-directed mutagenesis
revealed that only one out of the 2 potential sites was truly functional. Functional in vitro assays experimentally validated
that miR-155 can efficiently target KGF 39-UTR. Furthermore, in vivo experiments using a mouse model of lung fibrosis
showed that miR-155 expression level was correlated with the degree of lung fibrosis.
Conclusions/Significance: Our results strongly suggest a physiological function of miR-155 in lung fibroblasts. Altogether,
this study implicates this miRNA in the regulation by mesenchymal cells of surrounding lung epithelium, making it a
potential key player during tissue injury.
Citation: Pottier N, Maurin T, Chevalier B, Puisse ´gur M-P, Lebrigand K, et al. (2009) Identification of Keratinocyte Growth Factor as a Target of microRNA-155 in
Lung Fibroblasts: Implication in Epithelial-Mesenchymal Interactions. PLoS ONE 4(8): e6718. doi:10.1371/journal.pone.0006718
Editor: Dong-Yan Jin, University of Hong Kong, Hong Kong
Received April 17, 2009; Accepted July 7, 2009; Published August 24, 2009
Copyright:  2009 Pottier et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Canceropole PACA, the INCa (PL0079), the European Community (MICROENVIMET, FP7-HEALTH-F2-2008-201279),
‘‘Vaincre la Mucoviscidose’’ and the ‘‘Institut de Recherche en Environnement Industriel (IRENI). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: direction@ipmc.cnrs.fr (PB); mari@unice.fr (BM)
¤a Current address: Taub Institute, Columbia University, New York, New York, United States of America
¤b Current address: Institut National de Sante ´ et de Recherche Me ´dicale, U563, Centre de Physiopathologie de Toulouse-Purpan, Toulouse, France
. These authors contributed equally to this work.
Introduction
Epithelial-mesenchymal interactions are critical in regulating
many aspects of vertebrate embryo development and for the
maintenance of homeostatic equilibrium in adult tissues [1].
Stromal cells maintain control over epithelial cell proliferation,
survival and response to wounds and could also play a
collaborative role in pathological conditions such as cancer [2].
The interactions between epithelium and mesenchyme are
believed to be mediated by paracrine signals and extracellular
matrix (ECM) components secreted from fibroblasts thereby
affecting adjacent epithelia. In response to paracrine signals such
as cytokines and direct-cell contact from adjacent tumor epithelial
cells, fibroblasts undergo changes that may alter the normal
epithelial-mesenchymal interactions [3–5].
This is in particular the case during pulmonary fibrosis, where it
has been demonstrated that a variety of cytokines such as
transforming growth factor-beta (TGF-b), tumor necrosis factor-
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6718alpha (TNF-a), fibroblast growth factors (FGFs), interleukin-1 (IL-
1), monocyte chemoattractant protein-1 (MCP-1) are produced at
the sites of active fibrosis. These cytokines appear to be mostly
expressed by activated inflammatory cells, such as macrophages
and eosinophils [6]. A balance of pro-fibrogenic and anti-
fibrogenic forces generated by these networks of cytokines
determines the outcome of lung injury and inflammation. In vitro
studies of individual cytokines on fibroblasts has revealed a variety
of roles for these cytokines in the regulation of the fibrotic process,
such as mitogenic activity, stimulation of extracellular matrix and
alpha-smooth muscle actin gene expression, alteration of the
contractile phenotype, production of proteases, protease inhibitors,
chemokines, cytokines and growth factors [7].
Recently, microRNAs (miRNAs) have emerged as a major
class of gene expression regulators linked to many biological
functions. Since the first miRNA was identified in Caenorhabditis
elegans as an important factor for timing of larval development
[8,9], thousands of miRNAs have been characterized including
about 700 miRNAs in the human genome [10]. MiRNAs are
derived from a primary transcript called pri-miRNAs. The
current model of maturation includes primary nuclear cleavage
of pri-miRNAs by the RNase III endonuclease Drosha, which
liberates pre-miRNA hairpins. Hairpins are exported from the
nucleus to the cytoplasm, where they are cleaved by Dicer,
another RNase III endonuclease [11–13]. Dicer generates short
RNA sequences of about 22-nucleotides. MiRNAs are then
assembled with proteins of the Argonaute family into a
ribonucleoprotein complex: miRNP [14], which exhibits binding
complementarities with sequences usually located in the 39UTR
of the target transcript. The formation of a complex between
miRNP and a target leads to a repression of protein synthesis,
often associated with mRNA degradation [15]. Complex
formation follows a set of rules that have been substantiated by
experimental evidences [16–18]. The major determinant of the
interaction between the miRNA and its targets corresponds to a
short stretch of 6–8 nucleotides located 59 of the miRNA, called
the ‘‘seed’’. This implies that one miRNA can theoretically
interacts with hundreds of mRNAs [19]. Because several
miRNAs can also target the same transcript, the miRNA
regulatory network appears amazingly complex. To date, a small
proportion of miRNA targets have been validated and the exact
function of most miRNAs remains to be elucidated.
Dysregulation of these molecules, including miR-155 [20], has
been recently identified in the pathogenesis of inflammatory
diseases [20]. MiR-155 is contained within the only phylogenet-
ically conserved region of BIC RNA [21,22]. It has been linked to
cancer [23–26], viral infection [27] and immunity [28–31]. MiR-
155 has been shown to be induced by proinflammatory stimuli
such as lipopolysaccharides (LPS), Toll-like receptors (TLRs), IL-1
and TNF-a in macrophages and dendritic cells [32–34]. It has also
been detected in synovial fibroblasts and rheumatoid synovial
tissue [35]. Multiple targets for miR-155 have been identified in
several cell types and linked with the regulation of B and T cell
differentiation [29,30,36–38], TLR signalling in inflammatory
cells [34], or cellular adhesion in epithelial malignancies [39]. To
date, the putative function of miR-155 in fibroblasts remains
poorly documented [35,40].
T h ea i mo ft h ep r e s e n ts t u d yw a st o identify the repertoire of
miRNA expressed in fibroblasts and to characterize their
potential regulation by inflammatory cytokines. The detection
of miR-155 into these cells led us to investigate its relationship
with keratinocyte growth factor (KGF, FGF7), a central factor in
tissue repair that we are establishing as a direct target of miR-
155.
Results
miRNA expressed in normal lung fibroblast cells and their
modulation by inflammatory cytokines
We first analyzed the miRNA expression profile of normal
human pulmonary fibroblasts (HFL1, CCL-153) and compared it
with the miRNome of the alveolar epithelial cell line A549. Large
differences distinguish the 2 cell lines, such as a high expression of
the oncogenic miR-21 in the epithelial tumor cells or the restricted
expression of miR-199a, miR-143, miR-145 and miR-155 to
fibroblasts (Fig. 1A and Table S1). The detection of miR-155, a
major effector of B and T cells into fibroblasts confirm previous
studies indicating that this miRNA can be also detected in non
haematological tissues [40,41]. Because miR-155 has been
previously shown to be upregulated by inflammatory cytokines
in macrophages [32], we then analyzed the potential regulation of
miR-155 by inflammatory cytokines. Results indicate that miR-
155 was slightly induced by TNF-a and IL-1b while its level
decreased following TGF-b stimulation (Fig. 1B). Interestingly,
several other miRNAs, such as miR-29a/b, miR-30a, miR-125a/
b and miR-199 varied in a similar manner following stimulation,
with a milder effect of IL-1b relative to TNF-a (Fig. 1B). Levels of
mature miR-155 following treatment with the three cytokines were
determined by quantitative RT-PCR (Fig.1C). Cells were serum
starved 2 hours before treatment and subsequently stimulated
either for 4 h or 24 h. After 4 h of TNF-a and IL-1b stimulation,
the level of miR-155 displayed a slight increase while it decreased
in presence of TGF-b (Fig. 1C). A longer treatment led to a more
pronounced effect of TNF-a and TGF-b while the level of miR-
155 returned to its basal level in presence of IL1b. Of note, no
significant modulation of miR-155 could be observed in A549 cells
(data not shown).
MiR-155 expression in a mouse model of lung fibrosis
We then investigated the expression of miR-155 in a mouse
model of lung fibrosis, using the well-established bleomycin
instillation model. MiR-155 expression was measured by quanti-
tative RT-PCR on lungs from either sensitive C57BL/6 or
resistant BALB/c mice 7 and 14 days after bleomycin instillation
and compared with a PBS control (Fig. 2). Bleomycin impact on
two mouse strains was significantly different as evaluated by
survival and histopathological analysis, as previously described
[42]. Bleomycin led to an induction of miR-155 at both times in
the two strains. Interestingly, this induction appeared significantly
more pronounced in the sensitive C57BL/6 compared to the
resistant BALB/c mice (Fig. 2). Overall, these data indicated that
miR-155 can also be induced in an in vivo fibrogenic model and
that its expression level was correlated with the degree of lung
fibrosis.
mRNA profiling of miR-155-overexpressing fibroblasts
We then looked for fibroblast-specific targets of miR-155. To
that end, we transfected lung fibroblasts HFL1 either with a
synthetic pre-miR-155 or a ‘‘negative’’ pre-miRNA, used as a
control. Two independent experiments were carried out and the
expression of mature miR-155 was monitored with RQ-PCR. A
,500 fold induction of the miRNA was measured (data not
shown). We then used human pan genomic arrays [43] to
determine mRNA profiles and identify genes whose expression
levels changed following miR-155 overexpression. The analysis
was performed on RNA samples harvested at 24 h and 48 h post-
transfection, as suggested by recent similar studies [29,30,44].
Statistical analysis revealed changes in the expression of 474
g e n e s( 1 9 7u pa n d2 7 7d o w n - r e g u l a t e d )a n d1 4 0 4g e n e s( 6 1 9u p
miR-155 Function in Fibroblast
PLoS ONE | www.plosone.org 2 August 2009 | Volume 4 | Issue 8 | e6718and 785 dow-regulated) at 24 h and 48 h after transfection,
r e s p e c t i v e l y .A ss h o w ni nF i g .3 A ,t h ev a s tm a j o r i t yo fm o d u l a t e d
genes at 24 hours were also regulated at 48 hours. When the 2
sets of genes were analyzed by functional annotations, both lists
were associated with similar biological functions such as ‘‘cell-to-
cell signalling and interaction’’, ‘‘cell death’’ and ‘‘cellular
movement’’ (Table S2). Two distinct functional assays indeed
confirmed these predictions: firstly, caspase-3 activity was
increased in miR-155-transfected fibroblasts compared to
control cells (Fig. 4A), suggesti n gt h a tm i R - 1 5 5c o u l dp r o m o t e
apoptosis; Secondly, transfection of fibroblasts with miR-155
altered their migration. Cell motility was especially increased for
fibroblasts migrating on a type I-collagen substrate, for which
speed migration increased to 60% of basal (Fig. 4B). In
agreement with these data, analysis of scratch wound repair on
a collagen type I substrate indicated that a monolayer of
fibroblasts expressing mir-155 was more rapidly repaired than
a monolayer of control cells (Fig. 4C).
Figure 1. MiRNA expression data in human adenocarcinoma cells A549 and normal lung fibroblasts (CCD-19Lu) following a 24 h
stimulation with TNF-a, IL-1b or TGF-b. Cells were stimulated by the different cytokines and small RNA fraction from different biological
conditions were chemically labelled and hybridized on a miRNA microarray as described in the Materials and Methods section. (A) Heatmap
comparing control human pulmonary fibroblasts versus A549 adenocarcinoma cells. (B) Hierarchical clustering of miRNA modulated in normal human
pulmonary fibroblasts following stimulation with 10 ng/ml TNF-a, IL-1b and TGF-b. (C) Analysis of miR-155 expression levels by Taqman miRNA assay
following a 4 or 24 h stimulation by the 3 cytokines.
doi:10.1371/journal.pone.0006718.g001
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reduced level of expression of a population of transcripts that
corresponded to predicted targets of miR-155. Three independent
prediction tools (TargetScan, Pictar and MicroCible, see materials
and method section for calculation details) indicated an over-
representation of miR-155 predicted targets in the population of
down-regulated transcripts. Indeed, ,7 fold enrichment for the
presence of a 8-nucleotide sequence complementary to the miR-
155 ‘‘seed’’ was detected at 24 h (Fig. 3B). A ,3-fold enrichment
was noticed at 48 h (Fig. 3B). Different prediction tools provided
contrasted results, as visualized in the Venn diagrams depicted in
Fig. 2C. While a total of 260 transcripts were predicted by at least
one of this algorithm (Table S3), only 18 and 19 transcripts were
predicted by all 3 bioinformatics tools at 24 and 48 hours,
respectively. 15 transcripts were common to the 2 lists (Table 1).
Importantly, 9 out of these 15 transcripts (BACH1, H3F3A,
MAP3K7IP2, RAB11FIP2, SDCBP, SGK3, TOMM20,
TSPAN14, YWHAZ) have already been described as miR-155
targets in immune models [27,29,30,45]. This experimental
approach was also validated with the ‘‘Sylamer’’ approach
described in [46]. Overexpression of miR-155 in fibroblasts at
24 h and at 48 h clearly led to a down-regulation of transcripts
containing the following sequences in their 39UTR: ‘‘GCATTA’’,
‘‘GCATTAA’’, ‘‘AGCATTA’’, ‘‘AGCATTAA’’ (data not shown).
These sequences indeed correspond to the sequences complemen-
tary to the miR-155 ‘‘seed’’ region. We noticed that the best miR-
155 ‘‘seed’’ enrichment was obtained when predicted sites were
selected in the 39UTR rather than in the rest of the transcript (i.e.
in the open reading frame and in the 59UTR, data not shown).
FGF7/KGF is a miR-155 target
When we looked in the list of 15 transcripts whether one of these
putative miR-155 targets was specific to the fibroblasts, FGF-7, a
paracrine-acting epithelial mitogen produced by cells of mesen-
chymal origin, was identified. According to the TargetScanS
algorithm, sequence alignment of the miR-155 complementary
site in the 39-UTR of KGF mRNA in human, mouse and dog
allowed us to identify two conserved binding sites (Fig. 5A): i)
binding site one (‘‘seed’’ at position 1288–1293 and 1128–1133
after the transcription start site of the human and murine KGF
mRNA respectively) which contains conserved ‘‘seed’’ and
conserved anchoring adenosine ; ii) binding site two (‘‘seed’’ at
position 2017–2022 and 1824–1829 of the human and murine
KGF mRNA respectively) which contains both conserved ‘‘seed’’
and conserved anchoring adenosine plus a conserved Watson-
Crick match at the eighth nucleotide (Fig. 5A). To evaluate
whether miR-155 can alter the expression of KGF, we cloned a
fragment of 919 and 787 bp of the human and murine KGF 39-
UTR mRNA (NM_002009 and NM_008008) containing the two
putative miRNA-binding sites into the psiCHEK
TM-2 vector
(Fig. 3B) and transfected it into HEK 293 or NIH3T3 cells in the
presence of either a human or murine synthetic pre-miR-155
analogue or a pre-miR-control. After normalization of the Renilla
luciferase signal to the firefly luciferase signal, both human and
murine pre-miR-155 induced a significant decrease in the
normalized luciferase activity compared to control in the two cell
types (Fig. 5B, upper panels). This effect was dose dependent as
shown in Fig. 5B (lower panel).
Only miR-155-binding site 2 is functional
We then investigated whether one or both putative binding sites
in KGF 39UTR were functional. For this purpose, we generated
two mutants targeting each seed of the 2 putative binding sites:
MUT 1 for the putative binding site 1, MUT 2 for the putative
binding site 2. A third mutant was built with both mutations:
MUT1+MUT2 (Fig. 6A). Luciferase assay was performed with
mutant and wild type 39KGF UTR in HEK 293 cells. It
demonstrated that miR-155 still efficiently inhibited luciferase
activity after abrogation of the first seed while it had no inhibitory
effect on the activity of MUT2 (Fig. 6B), indicating that only site 2
was functional. As expected, the luciferase activity of the double
mutant was no more affected by miR-155. We next generated a
minimal construct corresponding to binding site 2 (from position
1815 to 1837 in the murine KGF transcript, Site2-1X) and an
additional construct containing a duplication of this sequence
(Site2-2X). In agreement with previous data, miR-155 significantly
inhibited the luciferase activity of the 2 constructs, the duplicated
site construct being even more sensitive than the wild type 39UTR
KGF construct (Fig. 6C). Overall, these results demonstrated that
only the second miR-155 binding site is functional in KGF 39-
UTR.
MiR-155 specifically attenuates inflammatory cytokines-
induced KGF release by lung fibroblasts
IL-1b is the most potent inducer of KGF in fibroblasts. Thus,
we first assessed whether miR-155 overexpression in human
fibroblasts could directly alter endogenous KGF release. Pre-miR-
155 or a control pre-miRNA were transfected in lung fibroblasts in
the presence or absence of IL-1b (10 ng/ml) and the production of
KGF and of 3 inflammatory cytokines (CCL5/RANTES, MCP-1
and IL-8) was measured (Fig. 7). As expected, IL-1b stimulation
led to a strong induction of all four factors and addition of pre-
miR-155 did not affect the expression level of CCL5 (Fig. 7A),
MCP1 (Fig. 7B) and IL-8 (Fig. 7C). Importantly, KGF release by
lung fibroblasts in response to IL-1b was significantly decreased in
cells transfected by miR-155 compared to control (Fig. 7D). The
specific fraction of KGF release corresponding to IL-1 induction
was indeed decreased to 45% of control (Fig. 7E). These results
Figure 2. MiR-155 expression is associated with lung fibrosis in
a murine model. Bleomycin-sensitive (C57BL/6) and resistant (BALB/c)
mice were treated with bleomycin or PBS and killed at various times
after instillation. Total RNA was extracted from lungs and miR-155
expression levels were performed by taqman miRNA assay. Histogram
represents miR-155 fold induction between bleomycin and PBS for the
2 mice strains 7 and 14 days after instillation (n=4 animals/group).
doi:10.1371/journal.pone.0006718.g002
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PLoS ONE | www.plosone.org 4 August 2009 | Volume 4 | Issue 8 | e6718Figure 3. A large number of predicted targets are repressed after overexpression of miR-155. Lung fibroblasts were transfected with a
synthetic pre-miR-155 or with a negative pre-miRNA (N=2). RNA samples were harvested at 24 and 48 h post-transfection. mRNA profiles were
determined with pan genomic arrays. (A) Heatmap comparing the normalized log2 of the ratios between pre-miR-155 signal and the pre-miR-Neg
signal, 24 h and 48 h after transfection. Clustering was performed using a Euclidian distance and a Ward method of agglomeration. Colours vary from
green for the lowest ratios to red for the highest ratios. (B) Over-representation of miR-155 seed complementary sequences in the 39-UTR of
downregulated transcripts. Using our bioinformatics tool ‘‘MicroTopTable’’ (see materials and method), representation of miRNA seed-binding
sequences in the set of up- or down-regulated genes was compared with the set of all expressed genes. For each miRNA seed, a fold enrichment
value (horizontal axis) and an associated P-Value (vertical axis) were calculated. The arrow indicates miR-155. (C) Venn diagram comparing the
number of miR-155 targets among the set of downregulated genes at 24 h and 48 h post-transfection according to 3 distinct target prediction tools
(TargetScan, Pictar and MicroCible).
doi:10.1371/journal.pone.0006718.g003
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PLoS ONE | www.plosone.org 5 August 2009 | Volume 4 | Issue 8 | e6718were confirmed by transfecting human lung fibroblasts either with
a LNA-antimiR-155 in order to block the endogenous expression
of miR-155 or with a pre-miR-155 in order to increase the
expression of miR-155 (Fig. 8A and 8B). Transfected cells were
treated for 72 or 96 hours with the inflammatory cytokines TNF-
a- or IL-1b. Interestingly, miR-155 knock-down was able to
potentiate KGF release in both TNF-a- and IL-1b-stimulated
HFL1. As expected, transfection of HFL1 with a pre-miR-155
strongly affected KGF release in the 3 culture conditions (Fig. 8A).
These results strongly suggest that miR-155 is involved in the
attenuation of KGF expression in lung fibroblasts following
inflammatory cytokines stimulation (Fig. 8C).
Discussion
We have demonstrated for the first time that miR-155 could
significantly decrease the relase of KGF induced by IL-1b or TNF-
a in human normal pulmonary fibroblasts. Since KGF plays a
central role in epithelial-mesenchymal interactions in lungs [47],
our data suggest that an alteration in miR-155 expression level
may have important pathophysiological impacts during acute lung
injury or pulmonary diseases.
Several studies have reported that miR-155 expression is
modulated in a number of physiological and pathological processes
such as hematopoiesis, immunity, tumorigenesis and inflammation
(for review, [48]). MiR-155 has been identified as a component of
the primary response to several inflammatory mediators in
different cell types [32–34]. It has been shown that miR-155 is
induced by lipopolysaccharide (LPS), interferon (IFN), polyriboi-
nosinic-polyribocytidylic acid (poly IC) or TNF-a in monocytes,
macrophages and dendritic cells [32–34,49]. In addition, nuclear
factor-kappa B and AP-1 transcription factors have been shown to
regulate miR-155 expression [32,50,51]. Our results showing the
stimulation of miR-155 by IL-1b and TNF-a in human
pulmonary fibroblasts fit well with these studies. These data are
consistent with the high levels of miR-155 detected in synovial
fibroblasts from Rheumatoid Arthritis patients, an autoimmune
disorder associated with high inflammation at joint level [35]. Our
observation showing an increased level of expression of miR-155
in a mouse model of lung fibrosis (Fig. 2) suggests a potential role
for miR-155 during this physio-pathological process. The precise
cellular location of miR-155 transcript has not been performed
yet. It is tempting to speculate that the weak induction of KGF
after stimulation by IL-1 observed in fibroblasts derived from
Figure 4. Transfection of human lung fibroblasts with pre-miR-155 increases caspase-3 activity and cell motility. Fibroblasts were
transfected with either pre-miR-Neg or pre-miR-155 (10 nM). (A) Caspase 3/7 assay was carried out 3 and 4 days following transfection using a specific
substrate as described in the method section (n=3). (B) A scratch wound was induced in confluent cell monolayers plated on plastic or on type I
collagen and individual cell migration speed was evaluated on 20 independant cells (n=2). (C) Representative experiment showing the percentage of
the repaired area in a scratch wound assay (n=2).
doi:10.1371/journal.pone.0006718.g004
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miR-155 Function in Fibroblast
PLoS ONE | www.plosone.org 7 August 2009 | Volume 4 | Issue 8 | e6718Figure 5. KGF mRNA is a primary target for miR-155. (A) Predicted interaction between miR-155 and the two putative binding sites in the KGF
39UTR. Alignment of human, mouse and dog sequences in the 39-UTR of KGF mRNA. The representation is limited to the region around the miR-155
complementary site. In bold, the ‘‘seed’’ region with a conserved anchoring adenosine (complementary to the first nucleotide of miR-155) and a
conserved WC match to the eighth nucleotide of the miRNA. This latter is only present in binding site 2. (B) Schematic representation of the construct
used in luciferase assay: a 919 bp and 787 bp region of the human and mouse KGF 39-UTR containing the two putative miR-155 target sites (arrows)
was cloned into the psiCHECK-2 vector. (C) Co-transfection of human or murine pre-miR-155 or pre-miR-Neg and of human or murine KGF 39UTR-
derived psiCHECK
TM-2 construct in HEK 293 and NIH 3T3 cells show a significant decrease in normalized luciferase activity 48 h post-transfection in
both cell types. Lower panel: dose-dependent inhibition of normalized luciferase activity in HEK 293 cells. ** indicates a p-value of less than 0.01 ina
Student’s t test.
doi:10.1371/journal.pone.0006718.g005
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PLoS ONE | www.plosone.org 8 August 2009 | Volume 4 | Issue 8 | e6718Figure 6. Only miR-155 putative binding site 2 is functional. (A) Generation by site-directed mutagenesis of murine fgf7 39-UTR mutants in
the ‘‘seed’’ of the putative binding sites (mutated bases are underlined): MUT 1 for the putative binding site 1, MUT 2 for the putative binding site 2
and a third mutant for both sites. (B) Co-transfection experiments of pre-miR-155 or pre-miR-Neg with these different constructs in HEK 293. Cells
were harvested two days after transfection and luciferase activities were analyzed. All renilla luciferase activities were normalized with firefly luciferase
activity. (C) HEK 293 cells were cotransfected with either pre-miR-155 or pre-miR-Neg together with different molecular constructs derived from pSI-
check2 in which the second putative miR-155 binding site in FGF7 mRNA has been cloned once (1X) or twice (2X) behind the renilla luciferase gene.
Cells were harvested two days after transfection, luciferase activities were analyzed and renilla luciferase activities were normalized with firefly
luciferase activity. ** indicates a p-value of less than 0.01 in a Student’s t test.
doi:10.1371/journal.pone.0006718.g006
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PLoS ONE | www.plosone.org 9 August 2009 | Volume 4 | Issue 8 | e6718patients with idiopathic pulmonary fibrosis (IPF) [52] is linked to
an over-expression of miR-155 into these cells. Additional studies
in the bleomycin-mouse model and on biopsies from IPF patients
will help clarifying this important point.
Studies in hematopoietic, immune, and inflammatory cells as
well as in hematologic and epithelial malignancies strongly suggest
that miR-155 is an essential molecule in the control of
myelopoeisis, erythropoiesis and B and T cell development. In
particular, the use of BIC/miR-155 deficient mice or transgenic
animals overexpressing miR-155 in B-cell lineage (E-miR-155)
have provided the identification of several important miR-155
targets in different immune cell types linked with its function in the
Figure 7. Transfection of human lung fibroblasts with pre-miR-155 inhibits IL-1b induced KGF release. Panels A-D show a representative
experiment of pre-miR-Neg or pre-miR-155 transfection (10 nM) effect on CCL5/RANTES, MCP-1, IL-8 and KGF release by lung fibroblast stimulated
with 10 ng/ml IL-1b. Results represent duplicates measurements of KGF by ELISA (R&D System) and duplicates measurements of CCL5, MCP-1 and IL-
8 by FACS Array
TM (human chemokine panel, Becton Dickinson) 48 h after transfection. Panel E summarizes the effect on KGF release by lung
fibroblast stimulated by IL-1b after transfection of pre-miR-Neg or of pre-miR-155. Results are expressed in percentage of KGF released after IL-1b
stimulation: pre-miR-155 decreases IL-1 b-mediated KGF release by approximately 45% compared to control. Results correspond to 3 independent
experiments performed in duplicates. ** indicates a p-value of less than 0.01 in a Student’s t test.
doi:10.1371/journal.pone.0006718.g007
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PLoS ONE | www.plosone.org 10 August 2009 | Volume 4 | Issue 8 | e6718activation of T and B lymphocytes, macrophages and dendritic
cells [28–30,33,37,38]. Interestingly, BIC-deficient mice displayed
significant remodeling of lung airways with age, associated with
increased bronchiolar subepithelial collagen deposition and
increased cell mass of sub-bronchiolar myofibroblasts. This is
perfectly in line with our own observation, showing that miR-155
could have also additional functions in fibroblasts. It has been
previously shown that miR-155 was expressed in primary lung
fibroblasts in which it could regulate human angiotensin II type 1
receptor expression [40]. However, other putative functions of
miR-155 in fibroblasts have not yet been documented. Our study
provides a first attempt to identify the functional impact of miR-
155 in normal human pulmonary fibroblasts.
In order to identify genes regulated by miRNAs in a specific
cellular context, we have combined in silico and experimental
approaches [53]. Several computational algorithms have been
developed elsewhere to predict transcripts targeted by miRNAs
[16,17,54,55]. They generally postulate that the 59 end of the
miRNA, known as the ‘‘seed’’ region, forms perfect matches with
the target sites and is usually conserved across species. However,
slight differences in the different algorithms often lead to very
distinct predictions. This clearly illustrates the limits of pure in silico
approaches, and plainly justifies an experimental verification of
these predictions. Incorporation of experimental data in the
pipeline of analysis can be useful in order to take into account
important parameters, such as the expression of the transcripts in a
specific cellular context. Among several experimental approaches
that are currently performed, the measurement of global gene
expression after an ectopic expression of a specific miRNA
deserves special interest. It usually induces a significant enrichment
of predicted targets among the set of down-regulated transcripts.
This suggests that most miRNAs, including miR-155 can indeed
induce degradation of their mRNA targets [30,44,56]. We have
validated this observation after alteration of several additional
miRNAs (Lebrigand et al, manuscript in preparation). In our study,
overexpression of miR-155 induces indeed a profound alteration
of mRNA profiles associated with an over-representation of
miRNAs predicted targets among the down-regulated transcripts.
We calculated an enrichment score for miR-155 predicted targets
in the set of downregulated transcripts, and compared it with the
score of all other miRNAs. An ordered list of the miRNA
compatible with a given set of downregulated transcripts was
established, using ‘‘MicroTopTable’’, a bioinformatics web tool
available at Mediante [73]. MicroTopTable also provided the
location of the binding sites on the transcripts and the energy of
complexes. It works with several possible prediction tools. All three
prediction tools used in the present study (i.e. TargetScan, Pictar
and MicroCible) performed similarly in terms of fold enrichment
and significance. The list of targets common to the three
bioinformatics tools only represented 7% of the total number of
transcripts predicted by at least one method. For the sake of
clarity, we restricted our work to the group with the strongest
typology, but other interesting candidates should be further
analyzed later. We also noticed that miR-155-associated target
enrichment already occurred at 24 hours (Fig. 2B), as already
suggested by others [57,58].
While the methodology described here worked finely for our
project, its general application can possibly be weakened by a few
limitations. A first possible drawback can be due to the high
expression of miR-155 caused by the transfection, which does not
reflect a physiological induction of this miRNA in HFL1. From
that perspective, a supra-physiological concentration of miR-155
might induce adverse effects through alteration of ‘‘low affinity’’
targets. This is probably not the case here, since a final
concentration of 0.15 nM of miR-155 induced a similar alteration
of HFL1 transcriptome (data not shown). A second drawback
could correspond to the saturation of the RISC complex by the
heterologous expression of small RNAs, leading to an altered
expression of genes controlled by endogenous miRNA, rather than
by miR-155 [59]. This is also unlikely in these experiments, since
we could not detect among upregulated transcripts any enrich-
ment for a group of mRNA targeted by one of the miRNA highly
expressed in fibroblasts. Based on our experience, we believe that
the comparison of miRNAs and mRNAs expression profiles
therefore provides a useful complement to pure computational
predictions based solely on sequence information. It remains that
even after such an analysis, the list of proposed miRNA targets still
Figure 8. miR-155 overexpression or knock-down regulates
KGF release in TNF-a-o rI L - 1 b stimulated human lung
fibroblasts. Panels A-B show a representative experiment of pre-
miR-Neg/pre-miR-155 (10 nM) or LNA-159s/LNA-155 (25 nM) transfec-
tion effect on KGF release by lung fibroblast stimulated or not during
48 hours with 10 ng/ml TNF-a or IL-1b. Results correspond to triplicates
measurements of KGF by ELISA (R&D System). *: p-value,0.05; **: p-
value,0.01. Panel C: model of miR-155-dependent attenuation of KGF
release following fibroblasts stimulation with inflammatory cytokines.
doi:10.1371/journal.pone.0006718.g008
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PLoS ONE | www.plosone.org 11 August 2009 | Volume 4 | Issue 8 | e6718require a direct validation by Western blot analyses and/or a
reporter plasmid assays.
Functional annotations of the microarrays experiments led to
the point that miR-155 has an impact on several biological
functions in fibroblasts related to pathways such as ‘‘cell-to-cell
signalling and interaction’’, ‘‘cell death’’ and ‘‘cellular movement’’
(Table S2). Of note, an induction of caspase-3 activity and an
increase in cell migration on type-I collagen was observed in
fibroblasts transfected with miR-155. Modifications in cell motility
can probably be linked to targeting of genes such as RHEB and
CYR61, two important regulators of cell adhesion, which were
validated by luciferase assays (Figure S1A). One biologically
relevant network drawn from the lists of genes that were
significantly modulated at 24 and at 48 h after miR-155
transfection is shown in Figure S1B. It contains five putative
miR-155 targets. One can notice the strong modulation of genes
associated with cell survival, such as Akt, and with migration, such
as proteases and integrins (in particular ITGB1, the integrin b1,
one of the type I collagen receptor subunit). In line with this
observation, a targeting by miR-155 of RhoA, a Rho GTPase, has
recently been reported elsewhere [39]. Importantly, our list of
putative miR-155 targets (Table S3) contains transcripts that were
also identified in murine hematopoietic systems (namely BACH1,
H3F3A, HIF1A, MAP3K7IP2, MYO10, RAB11FIP2, SDCBP,
SGK3, TOMM20, TSPAN14, WEE1, YWHAZ) [29,30,59,60].
Such a conservation among species is certainly indicative of the
likely impact of such interactions. Our list also share some
common candidates with a study that identified several miR-155
targets in human mature dendritic cells [34]: BACH1, CMAT1,
HNRPA3, MAP3K7IP7, PAPOLA and SERTAD2.
A central aspect of our work is related to the experimental
screening of miR-155 targets specific to fibroblasts. This allowed
the identification of KGF/FGF7, a central mediator of epithelial-
mesenchymal interaction as a direct target of miR-155. KGF is a
paracrine-acting, epithelial mitogen produced by cells of mesen-
chymal origin. KGF acts exclusively through FGFR2b, a subset of
FGF receptor isoforms (for review [47]). KGF has been shown to
be upregulated after epithelial injury in numerous conditions.
Preclinical data from several animal models demonstrated that
KGF could enhance the regenerative capacity of epithelial tissue
[61–64]. Despite the important function of KGF in lung, the
regulation of its production by lung fibroblasts is poorly
understood [52]. Inflammatory mediators are known stimulants
of KGF in fibroblasts. Among these mediators, IL-1b appears to
be the most potent inducer of KGF expression in fibroblasts
derived from multiple tissues [65,66]. Previous studies have
reported the presence of AP-1 sites in the promoter region of
mouse and human KGF genes [67]. In lung or dermal fibroblast,
it has been demonstrated that the IL-1b induced KGF secretion is
controlled through a balance between c-Jun and JunB. Indeed,
KGF expression was enhanced in JunB 2/2 fibroblast whereas
KGF was hardly detectable in c-jun 2/2 fibroblasts [68].
Our observation of a specific role for miR-155 in that context
appears of particular interest. Indeed, using KGF 39-UTR
luciferase constructs, we have demonstrated that KGF was a
direct target of miR-155. Interestingly, luciferase assay performed
with different KGF 39-UTR mutants for the two putative miR-155
binding sites showed that only binding site two was responsible of
miR-155-mediated KGF regulation. The binding site one contains
the conserved ‘‘seed’’ and the anchoring adenosine whereas the
binding site two contains also a conserved Watson-Crick match at
the eighth nucleotide (m8M, according to the nomenclature
established by [16]). This result indicates that the predicted
binding site one is a false positive due to the lack of a conserved
Watson-Crick match at the eighth nucleotide of the miRNA and is
in total agreement with previous studies reporting that the
presence of m8M decreased the possibility of false positive
compared to the sole presence of the ‘‘seed’’ and of the anchoring
adenosine [16,53]. This point seems of particular importance for
sites containing little 39 pairing support and ‘‘39 compensatory’’
sites such as the 2 binding sites discussed here.
We also demonstrated that miR-155 over-expression efficiently
inhibited endogenous KGF following stimulation with inflamma-
tory cytokines IL-1b and TNF-a. Conversely, miR-155 knock-
down using LNA-antimiR-155 was able to potentialize KGF
release in both TNF-a- or IL-1b-stimulated HFL1 at both times
(Fig. 5–6). Therefore, we propose a model in which both KGF
mRNA and miR-155-derived primary transcript BIC are induced
following inflammatory cytokines. According to this model, a
subsequent accumulation of miR-155 would attenuate KGF
production in a negative feedback mechanism (Fig. 8C). An
alternative model would be that miR-155 attenuates the
inflammatory intracellular pathway, as demonstrated recently
[34] by directly targeting adaptor molecules of the TLR/IL1
signaling cascade such as MAP3K7IP7/TAB2. However, al-
though TAB2 expression was found to be inhibited by miR-155 in
our microarray experiments, we clearly showed that miR-155
specifically inhibited IL1-induced KGF production but did not
affect the expression level of three other cytokines (CCL5, MCP1
and IL-8), indicating that in our model, miR-155 does not affect
the TLR/IL1 signalling cascade.
In conclusion, this study provides a global characterization of
miR-155 targets in human lung fibroblasts. It leads to the
identification of KGF/FGF7 as a mesenchymal-specific miR-155
target. To date, this is the first report relating evidence for miRNA
involvement in lung epithelial-mesenchymal interactions. Finally,
thisworkprovidesnewinsightsintothepathogenesisoflungfibrosis,
by suggesting a role for miRNAs in the lung fibrotic process.
Materials and Methods
Ethics statement
All animal care and experimental protocols were conducted in
accordance with the regulations of the institutional care and use
committee at the University of Lille 2. Personnel from the
laboratory carried out all experimental protocols under strict
guidelines to insure careful and consistent handling of the mice.
Cell Culture and Treatments
The human fibroblast cells HFL1 (CCL-153) derived from
normal lung tissue [69], adenocarcinoma A549 cells, NIH 3T3
and HEK 293 were purchased from the American Type Culture
Collection (Manassas, VA) and maintained in monolayer culture
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal calf serum (FCS). IL-1b, TNF-a and TGF-b
(Upstate) were used at final concentration of 10 ng/ml.
RNA isolation from cell samples
Total RNA were extracted from the samples with TRIzol
solution (Invitrogen, Carlsbad, CA, USA), and the integrity of
RNA was assessed by using an Agilent BioAnalyser 2100 (Agilent
Palo Alto, CA) (RIN above 7). The miRvana miRNA isolation kit
was used for isolation and enrichment of small RNA fractions
(Ambion, Austin, TX), according to the manufacturer’s protocol.
Animal treatment
9–12 weeks old male C57BL/6 and Balb/C mice were
purchased from Charles River, France. To induce fibrotic
miR-155 Function in Fibroblast
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PBS as previously described [42]. Briefly, mice were anesthetized
with sevoflurane inhalation (Abbott, UK) and placed in dorsal
recumbency. Transtracheal insertion of a 24-G animal feeding
needle was used to instillate bleomycin (0.75 unit/ml) or vehicle
(PBS), in a volume of 80 ml. Mice were sacrificed 7 and 14 days
after instillation and lungs were removed for further analysis. Lung
fibrosis was assessed by histopathology after fixation with 4%
paraformaldehyde/PBS overnight at 4uC. The major criteria
examined included interstitial thickening of alveolar or bronchi-
olar walls, collagen deposition, and inflammatory cell infiltration.
Total RNA was extracted from lungs removed from PBS- and
bleomycin-treated mice (n=4 for both strains) as described above
and used for assessment of miR-155 expression by quantitative
RT-PCR.
Microarray procedure
miRNA microarray procedure. The oligonucleotide se-
quences corresponding to 2054 mature miRNAs (409 homo sapiens)
found in the miRNA registry (Release 8.2; [10]) are available on
http://www.microarray.fr:8080/merge/index (follow the link to
‘‘Ipmc MicroRNA-1k microarray – v4)’’. Each oligonucleotide was
spotted fourtimes oneach microarray(2 distinct pairsof spots),in order
to reduce positional bias of the fluorescence readout. Experimental
data and associated microarray designs have been deposited in the
NBCI Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.
gov/geo/) under series GSE12033/GSE12035 and platform record
GPL4717. Target preparation and array hybridization were per-
formed as previously described [70,71]. Briefly, small RNA fraction
was purified from 100 mg total RNA with the miRvana miRNA
isolation kit (Ambion, Austin, TX) and 5 mgo fs m a l lR N Af r a c t i o n
were then chemically labeled with the Alexa fluors (Ulysis kit,
Invitrogen) as previously described [72]. Labeled RNA were then
combined, purified and hybridized in 300 ml hybridization buffer
(Agilent hybridization buffer) for 16 hrs at 48uCi nad y e - s w a p
experiment. Arrays were then washed once at room temp in Agilent
wash buffer (Agilent) for 5 min and then washed in Agilent wash buffer
II at 37uC for 30 sec, spun dry and scanned with a Genepix scanner
(Axon Instruments, Molecular Devices Corporation 3280 Whipple
Road Union City, CA 94587 USA). TIF images containing the data
from each fluorescence channel were quantified with the Genepix
pro 6.0 program (Axon Instruments) using a ‘circular features’
quantification method.
Expression microarray procedure. Pangenomic microa-
rrays were printed using human RNG/MRC oligonucleotide collec-
tion as previously described [43]. RNA were labelled and hybridized as
described in Moreilhon et al [73]. Two biological replicates were
performed for each comparison. Experimental data and associated
microarray designs have been deposited in the NCBI Gene Expression
Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/) under serie
GSE14477 and platform record GPL1456.
Statistical analysis. Normalizations were performed using
the limma package available from Bioconductor (http://www.
bioconductor.org). Intra slide and inter slide normalization were
performed using the Print Tip Loess and the quantile methods
respectively. Means of ratios from all comparisons were calculated
and and B test analysis was performed using the Limma package
available from Bioconductor. Differentially expressed genes were
selected using a Benjamini-Hochberg correction of the p-value for
multiple tests, based on a p-value below 0.05 and a fold change cut
off (logRatio.0.5).
Biological Theme Analysis. Data from expression micro-
arrays were analyzed for enrichment in biological themes (Gene
Ontology molecular function and biological process) and build
biological networks using Ingenuity Pathway Analysis software
(http://www.ingenuity.com/) and Mediante [74], an information
system containing diverse information about our probes set and
the data sets (http://www.microarray.fr:8080/merge/index).
Over-represented biological themes are shown in supplementary
Table S1.
MiR-155 targets analysis. Twoin-housebioinformaticstools
have been developed to predict miRNA targets (http://www.
microarray.fr:8080/merge/index follow the link to microRNA and
Bioinformatic tools): i) MicroCible is a miRNA target predictor that
scans transcripts sequences for the presence of ‘‘miRNA seed’’
complementary sequence. This search can be performed for
different ‘‘seed’’ match type [53], a minimal free energy binding
cutoff, and the location of the potential targeting site (i.e. 39UTR or
entire transcript) ; ii) MicroTopTable is dedicated to the search of
putative enrichments in miRNA predicted binding sites among a set
of modulated genes for different prediction softwares (i.e. Miranda,
MicroCible, TargetScan or PicTar). MicroTopTable ranks the
transcripts into three categories (‘‘Upregulated’’, ‘‘Down regulated’’
and ‘‘non-modulated’’), according to thresholds for expression level
and for differential expression. MicroTopTable then calculates the
number of predicted targets for each miRNA, according to the
prediction software selected, in each of the three categories.
Enrichment in miRNA targets in each category is then tested
using the hypergeometric function.
Quantitative RT-PCR of mature miRNA
MiR-155 expression in cytokines-stimulated fibroblasts was
evaluated using TaqMan MicroRNA Assay (Applied Biosystems,
Foster City, CA) as specified in their protocol. Real-time PCR was
performed using GeneAmp Fast PCR Master Mix (Applied
Biosystems, Foster City, CA) and ABI 7900HT real-time PCR
machine. All reactions were performed in duplicate. Expression
levels of mature microRNAs were evaluated using comparative
CT method (2-deltaCT). Transcript levels of let-7a and RNU6B
was used as endogenous control.
Molecular constructs
Various molecular constructs were derived from psiCHECK
TM-
2 (Promega) by cloning behind the renilla luciferase ORF sequences
from fgf7 39-UTR mRNA. For human and murine full lenght KGF
39UTR cloning, a 919 and 787 nt sequence encompassing two
putative miR-155 binding sites from human and mouse FGF7 39
UTR respectively was amplified using the primers listed in ‘‘Online
Supplementary Materials S1’’ and cloned in the XhoI and NotI
restrictions sites. Mutations were introduced by site-directed
mutagenesis in mice fgf7 39UTR miR-155 putative binding sites
using the QuickChange Kit (Stratagene). Primers used for site-
directed mutagenesis arelistedin ‘‘OnlineSupplementary Materials
S1’’. In order to analyze in details the sequence targeted by miR-
155 in fgf7 39UTR we derived several constructs from the second
miR-155 binding site. Complementary oligonucleotides referenced
in ‘‘Online Supplementary Materials S1’’ (50 mM final concentra-
tions) were mixed with 10X Oligo Annealing Buffer (Invitrogen)
heated 95uC for 4 minutes and allowed to cool at room temperature
for 10 min. Diluted (10 nM) dsDNA were subsequently cloned in
XhoI/NotI restriction sites in the pSI-Check2 (Promega). Site2-1X
corresponds to the sequence 1815 to1837 of the murine fgf7
messenger. In the Site2-2X, the 22 nt sequence emcompassing the
miR-155 ‘‘seed’’ match has been duplicated.
Transfection and luciferase assays
Pre-miRNAs overexpression in HFL1. pre-miR-155 and
control miRNA (miR-Neg # 1) were purchased from Ambion.
miR-155 Function in Fibroblast
PLoS ONE | www.plosone.org 13 August 2009 | Volume 4 | Issue 8 | e6718HFL1 cells were grown in 10% FCS in DMEM and transfected at
50% confluency in 6-well plates using Lipofectamin RNAi
MAX
TM(InVitrogen) with pre-miRNA at a final concentration
of 10 nM.
Pre-miRNAs and psiCHECK
TM-2 plasmid constructs co-
transfection. NIH 3T3 and HEK 293 cells were cultured in 10%
FCS in DMEM until confluency. Then, cells were plated into 48-well
plates at a density of 26.5 10
3 cells/well and cotransfected using
lipofectamin 2000
TM (InVitrogen) with 0.4 mg of psiCHECK
TM-2
plasmid construct and pre-miR-155 or control miRNA at a final
concentration of 10 nM. 48 hours after transfection, Firefly and
Renilla Luciferase activities were measured using the Dual-Glo
TM
Luciferase assay (Promega).
Assessment of KGF production from lung fibroblast. Pre-
miR-155 and control miRNA (miR-Neg # 1) were purchased from
Ambion; LNA anti-miR-155 and a control LNA inhibitor (LNA-
159s) were purchased from Exiqon. Adult or embryonnal lung
fibroblast cells were cultured in 10% FCS in DMEM until
confluency. Then, cells were plated into 6-well plates at a density
of 4.10
6 cells/well and transfected using lipofectamin RNAi
MAX
TM (InVitrogen) with pre-miRNAs or LNA-anti-miRs at a
final concentration of 10 nM and 25 nM respectively. Twenty four
hours after transfection, cells were washed in PBS, and medium was
replacedbyDMEMwithoutserum.Thencellswere stimulated with
IL-1b or TNF-b at a final concentration of 10 ng/ml. At different
times after stimulation, supernatants were collected and KGF was
measured by ELISA kit purchased from R&D Systems according to
manufacturer’s protocol.
Cytokine assay
MCP-1, IL-8 and CCL5 assays were performed using the BD
FACSArray
TM Bioanalyser (BD Biosciences, Le Pont de Claix,
France) according to manufacturer’s protocol. Cytokine assays
were measured in 50 ml of conditioned media.
Caspase 3/7 assay
The activation of executioner caspase-3 and -7 was determined
using the Caspase-Glo 3/7 Assay kit according to manufacturer’s
instructions from Promega (Madison, WI). Cells were plated in
triplicate in 96-well plates and transfected as described above.
Samples were read after 1 hr of incubation with the caspase
substrate on a luminometer .
In Vitro Wound-Scratching Assay
Cells were plated on noncoated or collagen-type I-coated 12-
well plates and transfected as described above. Twenty four hours
after transfection, confluent cells were wounded by a pipet tip. The
in vitro wound-healing process was then recorded by videomicro-
scopy for 24 h from the scratching on an Axiovert 200 M inverted
microscope (Carl Zeiss, Le Pecq, France) equipped with 37uC and
5% CO2 regulated insert (Pecon GmbH, Germany). Brightfied
images were taken each hour through a 106 phase contrast
objective with a CoolSNAPHQ CCD Camera managed by
Metamorph Software (Roper Scientific, Evry, France). The
motility of the cells was evaluated by the determination of the
repaired area percentage and of the cell migration speed using the
ImageJ sotware.
Statistical analysis
R e s u l t sa r eg i v e na sm e a n 6S.E.M. Statistical analyses were
performed by using Student’s t-test as provided by Microsoft
Excel
TM and the null hypothesis was rejected at the 0.05
level.
Supporting Information
Online Supplemental Material S1
Found at: doi:10.1371/journal.pone.0006718.s001 (0.04 MB
DOC)
Figure S1 Validation of miR-155 targets and hypothetic model
of miR-155 in the regulation of fibroblasts apoptosis and motility.
(A) miR-155 targets 39UTR mRNAs of RHEB, POLE3, CYR61
and H3F3A. HEK 293 cells were co-transfected with pre-miR-155
or pre-miR-Neg and different pSi-CHECK constructs as de-
scribed in the Materials and Methods section. Transfection of pre-
miR-155 induces a significant decrease in normalized luciferase
activity 48 h post-transfection for all 39UTR tested. (B) Ingenuity
Pathway Analysis identifies a network of genes potentially mo-
dulated by miR-155 and involved in cell survival and migration.
The network is displayed graphically as nodes (genes/gene
products) and edges (the biological relationships between the
nodes). Red and green nodes correspond to up- and down-
regulated genes after a 24 (left) or 48 h (right) pre-miR-155
transfection experiment. As described in the legend provided,
nodes are displayed using various shapes that represent the
functional class of the gene product. Edges are displayed with
various labels that describe the nature of the relationship between
the nodes (A, activation; B, binding; E, expression; I, inhibition; P,
phosphorylation; T, transcription). Edges without a label represent
binding only. Grey nodes were identified by the pathway analysis
as part of the network. The putative inhibitory action of miR-155
on 5 gene products has been represented. AREG: amphiregulin;
ADAM: ADAM metallopeptidase domain; CTGF: connective
tissue growth factor; CYR61: cysteine-rich, angiogenic inducer,
61; FERMT2: fermitin family homolog 2; IGFBP3: insulin-like
growth factor binding protein 3; ITGAV: integrin, alpha V;
ITGB: integrin, beta; JAM: junctional adhesion molecule; MMP1:
matrix metallopeptidase 1; MYO10: myosin X; PKN2: protein
kinase N2; PRKCI: protein kinase C, iota; RHEB: Ras homolog
enriched in brain; SH3D19: SH3 domain containing 19; SULF1:
sulfatase 1; THBS2: thrombospondin 2; VCAN: versican.
Found at: doi:10.1371/journal.pone.0006718.s002 (0.98 MB TIF)
Table S1 Main differentially expressed miRNAs between HFL1
and A549 cells. RNG oligo IDs give access to transcripts and
probes annotations through our system of information Mediante
(http://www.microarray.fr:8080/merge/index). Expression values
correspond to the mean of fluorescence intensity for each probe.
Found at: doi:10.1371/journal.pone.0006718.s003 (0.05 MB
PDF)
Table S2 GO Database functional analysis of the genes
regulated in response to miR-155 overexpression. Most significant
themes identified by Ingenuity Pathway analysis. The genes
modulated between miR-155 and miR-Neg transfected samples at
two time points (24 h and 48 h) are listed in each case. The p value
was calculated as a Fisher’s exact probability.
Found at: doi:10.1371/journal.pone.0006718.s004 (0.10 MB
PDF)
Table S3 Full list of the miR-155 predicted targets down-
regulated following miR-155 overexpression in HFL1. The 260
transcripts predicted to be miR-155 targets by at least one of the
following algorithm: TargetScan, Pictar and MicroCible, are
listed. Logarithm (base 2) of the ratio of miR-155/miR-Neg and
false discovery rate p-values using the Benjamini-Hochberg
correction are represented. ID: correspond to RNG oligo IDs
that give access to transcripts and probes annotations through our
system of information Mediante (http://www.microarray.fr:8080/
merge/index).
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